In clinical trials, patients lost 1522% of body weight , outperforming even semaglutide
So far, the trials seem to show: high reduction in weight, hovering around 28% for those on a 12-milligram dose self-reported improvements in cardiometabolic risk factors like high blood pressure, insulin, and fasting glucose promising results for type 2 diabetes and fatty liver disease a reduction in pain from knee osteoarthritis Retatrutide may be valuable for those who have had limited success with other weight loss drugs, have a higher BMI, or are at significant metabolic risk
Avoid carrying commercial quantities or unlabeled vials through international borders, as this can trigger additional screening and delays
TRULICITY 1.5 mg solution for injection in pre-filled pen Summary of Product Characteristics
Back Brown, JC, Mutt, V, Pederson, RA (July 1970) 'Further purification of a polypeptide demonstrating enterogastrone activity', The Journal of Physiology , 209/1